Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins.
10.3343/alm.2015.35.3.329
- Author:
Ye DOU
1
;
Xiaohai ZHU
;
Qinglu WANG
;
Xuewen TIAN
;
Jingjing CHENG
;
Enying ZHANG
Author Information
1. Key Laboratory of Biomedical Engineering & Technology of Shandong High School, Shandong Wanjie Medical College, Zibo, China. wql_zcq@126.com
- Publication Type:Meta-Analysis ; Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
SLCO1B1 gene;
Statins;
Lipid-lowering effect;
Meta-analysis
- MeSH:
Alleles;
Databases, Factual;
Genotype;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use;
Hyperlipidemias/drug therapy/genetics;
Polymorphism, Single Nucleotide;
Solute Carrier Organic Anion Transporter Family Member 1b1/*genetics
- From:Annals of Laboratory Medicine
2015;35(3):329-335
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Several studies have focused on the association between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism; however, the results are conflicting. The effects of statins show significant variability between individuals. This meta-analysis aimed to investigate the effects of the SLCO1B1 c.521T>C polymorphism on the lipid-lowering effects of statins. METHODS: We systematically searched PubMed and Web of Science to screen relevant studies. Meta-analysis was performed to identify the association between SLCO1B1 c.521 polymorphisms and the lipid-lowering effects of statinson the basis of the standard mean difference (SMD) and 95% confidence intervals (CIs). Additionally, we checked for heterogeneity (I 2) among studies and evidence of publication bias. We obtained eight studies including 2,012 wild genotype (T/T) and 526 variant genotype (T/C and C/C) cases. RESULTS: No significant difference was observed in the lipid-lowering efficacy of statins between the wildand variant genotypes of SLCO1B1, with a pooled SMD of 0.03 (95% CI: -0.07-0.13). Furthermore, there was no significant effect in the meta-analyses of the variant heterozygote, homozygote, and Chinese populations. Subgroup meta-analysis indicated that the timerequired for the statin to take effectdid notsignificantly affect the association between lipid-lowering efficacy of statins and SLCO1B1 c.521T>C polymorphism. However, thewild genotype improved the lipid-lowering efficacy of simvastatin with a pooled SMD of -0.26 (95% CI: -0.47- -0.05). CONCLUSIONS: No significant association was detected between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism, with the exception of simvastatin.
